ערך בספרים למניה: IDEAYA Biosciences (IDYA)

The price trajectory of IDEAYA Biosciences (IDYA) shown below is based on an asset-light model, where R&D is concentrated in the US and production is outsourced to CMO partners, ensuring the 12.50 metric. IDEAYA Biosciences is implementing breakthrough synthetic lethality methods, creating inhibitors for the therapy of melanoma and solid tumors. However, success depends on the speed of registration, as lagging behind market behemoths depreciates the developments.

Book value per share determines the actual coverage of a security through the company's net assets. This metric is calculated as the difference between all assets and liabilities, divided by the number of shares. By analyzing the BVPS indicator on the GURU.Markets platform, an investor assesses the intrinsic value of the business. For IDEAYA Biosciences (IDYA), the trend reflects R&D expenditures. Rising costs associated with scaling tests directly impact capital prior to the conclusion of licensing deals.